Chronic Lymphocytic Leukemia Patients Have a Preserved Cytomegalovirus-Specific Antibody Response despite Progressive Hypogammaglobulinemia

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Vanura, Katrina ^a   Rieder, Franz ^a   Kastner, Marie Theres ^a   Biebl, Julia ^a   Sandhofer, Michael ^a   Le, Trang ^a   Strassl, Robert ^a   Puchhammer Stöckl, Elisabeth ^a   Perkmann, Thomas ^a   Steininger, Christoph F ^a   Stamatopoulos, Kostas ^b   Graninger, Wolfgang ^a   Jäger, Ulrich ^a   Steininger, Christoph ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b G PAPANICOLAOU HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYTOMEGALOVIRUS ANTIBODY; GLYCOPROTEIN B; IMMUNOGLOBULIN G ANTIBODY; VIRUS DNA; IMMUNOGLOBULIN G; MATRIX PROTEIN; PHOSPHOPROTEIN; PP150 PROTEIN, CYTOMEGALOVIRUS; PRIMER DNA; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN PRESENTATION; ARTICLE; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DNA DETERMINATION; EPSTEIN BARR VIRUS INFECTION; FEMALE; GENETIC VARIABILITY; HERPES ZOSTER; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NONHUMAN; PROSPECTIVE STUDY; VIREMIA; VIRUS REACTIVATION; AGAMMAGLOBULINEMIA; ANTIBODY PRODUCTION; BIOLOGICAL MODEL; BLOOD; CYTOMEGALOVIRUS; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGY; KINETICS; MOLECULAR GENETICS; NUCLEIC ACID AMPLIFICATION; NUCLEOTIDE SEQUENCE; PHYLOGENY; SPECIES DIFFERENCE; STATISTICAL MODEL;

AGAMMAGLOBULINEMIA; ANTIBODIES, VIRAL; ANTIBODY FORMATION; BASE SEQUENCE; CYTOMEGALOVIRUS; DNA PRIMERS; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN G; KINETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LIKELIHOOD FUNCTIONS; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PHOSPHOPROTEINS; PHYLOGENY; PROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; SPECIES SPECIFICITY; VIRAL MATRIX PROTEINS; VIREMIA;

EID: 84885972444     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078925     Document Type: Article

References (49)

1. Tsiodras S, Samonis G, Keating MJ, Kontoyiannis DP, (2000) Infection and immunity in chronic lymphocytic leukemia. Mayo Clin Proc 75: 1039-1054. doi:10.4065/75.10.1039. PubMed: 11040852.
2. Molica S, Levato D, Levato L, (1993) Infections in chronic lymphocytic leukemia. Analysis of incidence as a function of length of follow-up. Haematologica 78: 374-377. PubMed: 8175032.
3. Morrison VA, (2009) Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis. Clin Lymphoma Myeloma 9: 365-370. doi:10.3816/CLM.2009.n.071. PubMed: 19858055.
4. Wadhwa PD, Morrison VA, (2006) Infectious complications of chronic lymphocytic leukemia. Semin Oncol 33: 240-249. doi:10.1053/j.seminoncol.2005.12.013. PubMed: 16616071.
5. Crnkovic I, Lucin P, Koszinowski UH, (1994) Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J Exp Med 179: 1713-1717. doi:10.1084/jem.179.5.1713. PubMed: 8163949.
6. Wang D, Shenk T, (2005) Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci U S A 102: 18153-18158. doi:10.1073/pnas.0509201102. PubMed: 16319222.
7. Daniels JA, Lederman HM, Maitra A, Montgomery EA, (2007) Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID): a clinicopathologic study and review. Am J Surg Pathol 31: 1800-1812. doi:10.1097/PAS.0b013e3180cab60c. PubMed: 18043034.
8. Kainulainen L, Nikoskelainen J, Vuorinen T, Tevola K, Liippo K, et al. (1999) Viruses and bacteria in bronchial samples from patients with primary hypogammaglobulinemia. Am J Respir Crit Care Med 159: 1199-1204. doi:10.1164/ajrccm.159.4.9807067. PubMed: 10194166.
9. Malphettes M, Gérard L, Carmagnat M, Mouillot G, Vince N, et al. (2009) Late-onset combined immune deficiency: a subset of common variable immunodeficiency with severe T cell defect. Clin Infect Dis 49: 1329-1338. doi:10.1086/606059. PubMed: 19807277.
10. Steininger C, Kundi M, Kletzmayr J, Aberle SW, Popow-Kraupp T, (2004) Antibody maturation and viremia after primary cytomegalovirus infection, in immunocompetent patients and kidney-transplant patients. J Infect Dis 190: 1908-1912. doi:10.1086/424677. PubMed: 15529253.
11. Brinkhof MW, Mayorga O, Bock J, Heininger U, Herzog C, (2013) Kinetics of maternally acquired anti-hepatitis A antibodies: prediction of waning based on maternal or cord blood antibody levels. Vaccine 31: 1490-1495. doi:10.1016/j.vaccine.2013.01.011. PubMed: 23328312.
12. Leuridan E, Goeyvaerts N, Hens N, Hutse V, Van Damme P, (2012) Maternal mumps antibodies in a cohort of children up to the age of 1 year. Eur J Pediatr 171: 1167-1173. doi:10.1007/s00431-012-1691-y. PubMed: 22395563.
13. La Rosa C, Wang Z, Lacey SF, Markel SF, Sharma MC, et al. (2005) Characterization of host immunity to cytomegalovirus pp150 (UL32). Hum Immunol 66: 116-126. doi:10.1016/j.humimm.2005.08.222. PubMed: 15694996.
14. Lazzarotto T, Maine GT, Dal Monte P, Ripalti A, Landini MP, (1997) A novel Western blot test containing both viral and recombinant proteins for anticytomegalovirus immunoglobulin M detection. J Clin Microbiol 35: 393-397. PubMed: 9003603.
15. Beghetto E, Paolis FD, Spadoni A, Del Porto P, Buffolano W, et al. (2008) Molecular dissection of the human B cell response against cytomegalovirus infection by lambda display. J Virol Methods 151: 7-14. doi:10.1016/j.jviromet.2008.04.005. PubMed: 18499273.
16. Gandhi MK, Khanna R, (2004) Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 4: 725-738. doi:10.1016/S1473-3099(04)01202-2. PubMed: 15567122.
17. Steininger C, Widhopf GF, Ghia EM, Morello CS, Vanura K, et al. (2012) Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen. Blood 119: 2293-2301. doi:10.1182/blood-2011-08-374058. PubMed: 22234695.
18. Steininger C, Schmied B, Sarcletti M, Geit M, Puchhammer-Stöckl E, (2005) Cytomegalovirus genotypes present in cerebrospinal fluid of HIV-infected patients. AIDS 19: 273-278. PubMed: 15718837.
19. Chou SW, Dennison KM, (1991) Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes. J Infect Dis 163: 1229-1234. doi:10.1093/infdis/163.6.1229. PubMed: 1709960.
20. Puchhammer-Stöckl E, Görzer I, (2006) Cytomegalovirus and Epstein-Barr virus subtypes--the search for clinical significance. J Clin Virol 36: 239-248. doi:10.1016/j.jcv.2006.03.004. PubMed: 16697698.
21. Widhopf GF, Rassenti LZ, Toy TL, Gribben JG, Wierda WG, et al. (2004) Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood 104: 2499-2504. doi:10.1182/blood-2004-03-0818. PubMed: 15217828.
22. Buhl AM, Jurlander J, Geisler CH, Pedersen LB, Andersen MK, et al. (2006) CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia. Eur J Haematol 76: 455-464. doi:10.1111/j.0902-4441.2005.t01-1-EJH2530.x. PubMed: 16529606.
23. Allan JM, Sunter NJ, Bailey JR, Pettitt AR, Harris RJ, et al. (2010) Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia. Leukemia 24: 877-881. doi:10.1038/leu.2009.298. PubMed: 20090783.
24. Dati F, Johnson AM, Whicher JT, (2001) The existing interim consensus reference ranges and the future approach. Clin Chem Lab Med 39: 1134-1136. PubMed: 11831629.
25. Engelmann I, Petzold DR, Kosinska A, Hepkema BG, Schulz TF, et al. (2008) Rapid quantitative PCR assays for the simultaneous detection of herpes simplex virus, varicella zoster virus, cytomegalovirus, Epstein-Barr virus, and human herpesvirus 6 DNA in blood and other clinical specimens. J Med Virol 80: 467-477. doi:10.1002/jmv.21095. PubMed: 18205230.
26. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, et al. (2011) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28: 2731-2739. doi:10.1093/molbev/msr121. PubMed: 21546353.
27. Kostareli E, Hadzidimitriou A, Stavroyianni N, Darzentas N, Athanasiadou A, et al. (2009) Molecular evidence for EBV and CMV persistence in a subset of patients with chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors. Leukemia 23: 919-924. doi:10.1038/leu.2008.379. PubMed: 19148139.
28. Greijer AE, van de Crommert JM, Stevens SJ, Middeldorp JM, (1999) Molecular fine-specificity analysis of antibody responses to human cytomegalovirus and design of novel synthetic-peptide-based serodiagnostic assays. J Clin Microbiol 37: 179-188. PubMed: 9854087.
29. Novák J, Sova P, Krchnák V,; Hamsíková E, Závadová H, et al. (1991) Mapping of serologically relevant regions of human cytomegalovirus phosphoprotein pp150 using synthetic peptides. J Gen Virol 72: 1409-1413. doi:10.1099/0022-1317-72-6-1409. PubMed: 1710650. doi:10.1099/0022-1317-72-6-1409 PubMed: 1710650.
30. Takahashi I, Sugiura S, Ohta H, Ozawa K, Kamiya T, (2002) Epitope analysis of antibodies in Japanese to human cytomegalovirus phosphoprotein 150 with synthetic peptides. Biosci Biotechnol Biochem 66: 2402-2405. doi:10.1271/bbb.66.2402. PubMed: 12506979.
31. Schäfer P, Tenschert W, Cremaschi L, Gutensohn K, Laufs R, (1998) Utility of major leukocyte subpopulations for monitoring secondary cytomegalovirus infections in renal-allograft recipients by PCR. J Clin Microbiol 36: 1008-1014. PubMed: 9542927.
32. Silva MC, Yu QC, Enquist L, Shenk T, (2003) Human cytomegalovirus UL99-encoded pp28 is required for the cytoplasmic envelopment of tegument-associated capsids. J Virol 77: 10594-10605. doi:10.1128/JVI.77.19.10594-10605.2003. PubMed: 12970444.
33. Sanchez V, Greis KD, Sztul E, Britt WJ, (2000) Accumulation of virion tegument and envelope proteins in a stable cytoplasmic compartment during human cytomegalovirus replication: characterization of a potential site of virus assembly. J Virol 74: 975-986. doi:10.1128/JVI.74.2.975-986.2000. PubMed: 10623760.
34. Baxter MK, Gibson W, (2001) Cytomegalovirus basic phosphoprotein (pUL32) binds to capsids in vitro through its amino one-third. J Virol 75: 6865-6873. doi:10.1128/JVI.75.15.6865-6873.2001. PubMed: 11435566.
35. Sampaio KL, Cavignac Y, Stierhof YD, Sinzger C, (2005) Human cytomegalovirus labeled with green fluorescent protein for live analysis of intracellular particle movements. J Virol 79: 2754-2767. doi:10.1128/JVI.79.5.2754-2767.2005. PubMed: 15708994.
36. Varnum SM, Streblow DN, Monroe ME, Smith P, Auberry KJ, et al. (2004) Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J Virol 78: 10960-10966. doi:10.1128/JVI.78.20.10960-10966.2004. PubMed: 15452216.
37. Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, Sinclair JH, (1991) Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol 72: 2059-2064. doi:10.1099/0022-1317-72-9-2059. PubMed: 1654370.
38. Mackus WJ, Frakking FN, Grummels A, Gamadia LE, De Bree GJ, et al. (2003) Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia. Blood 102: 1057-1063. doi:10.1182/blood-2003-01-0182. PubMed: 12689926.
39. Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, et al. (2013) T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 121: 1612-1621. doi:10.1182/blood-2012-09-457531. PubMed: 23247726.
40. Pourgheysari B, Bruton R, Parry H, Billingham L, Fegan C, et al. (2010) The number of cytomegalovirus-specific CD4+ T cells is markedly expanded in patients with B-cell chronic lymphocytic leukemia and determines the total CD4+ T-cell repertoire. Blood 116: 2968-2974. doi:10.1182/blood-2009-12-257147. PubMed: 20562332.
41. Kater AP, Evers LM, Remmerswaal EB, Jaspers A, Oosterwijk MF, et al. (2004) CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. Br J Haematol 127: 404-415. doi:10.1111/j.1365-2141.2004.05225.x. PubMed: 15521917.
42. Pourgheysari B, Khan N, Best D, Bruton R, Nayak L, et al. (2007) The cytomegalovirus-specific CD4+ T-cell response expands with age and markedly alters the CD4+ T-cell repertoire. J Virol 81: 7759-7765. doi:10.1128/JVI.01262-06. PubMed: 17409149.
43. Stowe RP, Kozlova EV, Yetman DL, Walling DM, Goodwin JS, et al. (2007) Chronic herpesvirus reactivation occurs in aging. Exp Gerontol 42: 563-570. doi:10.1016/j.exger.2007.01.005. PubMed: 17337145.
44. Koch S, Larbi A, Ozcelik D, Solana R, Gouttefangeas C, et al. (2007) Cytomegalovirus infection: a driving force in human T cell immunosenescence. Ann N Y Acad Sci 1114: 23-35. doi:10.1196/annals.1396.043. PubMed: 17986574.
45. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, et al. (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99: 3554-3561. doi:10.1182/blood.V99.10.3554. PubMed: 11986207.
46. Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, et al. (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25: 5616-5623. doi:10.1200/JCO.2007.12.9098. PubMed: 17984186.
47. Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, et al. (2006) Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 43: 16-24. doi:10.1086/504811. PubMed: 16758413.
48. Silverman GJ, Goodyear CS, (2006) Confounding B-cell defences: lessons from a staphylococcal superantigen. Nat Rev Immunol 6: 465-475. doi:10.1038/nri1853. PubMed: 16724100.
49. Goodyear CS, Silverman GJ, (2005) B cell superantigens: a microbe's answer to innate-like B cells and natural antibodies. Springer Semin Immunopathol 26: 463-484. doi:10.1007/s00281-004-0190-2. PubMed: 15633015.